Table 2.
223Ra toxicity in patients with metastatic castration-resistant prostate cancer
Toxicities (grade 3/4) | Phase II study35 n=100 | Phase II study28 n=122 | Phase III study29 n=921 223Ra vs placebo | Phase III-b study32 | Retrospective study33 |
---|---|---|---|---|---|
Hematological | |||||
Anemia | 8% | 7% | 13% vs 13% | 12% | 5% |
Thrombocytopenia | 6% | 2% | 12% vs 6% | 3% | 5% |
Neutropenia | 3% | <1% | 3% vs 1% | 2% | 4% |
Gastrointestinal | |||||
Diarrhea | NR | 0 | 25% vs 15% | 1% | NR |
Nausea | NR | 0 | 2% vs 2% | <1% | NR |
Abbreviations: 233Ra, radium-223; NR, not reported.